Compound Promising Against Resistant Prostate Cancers

[Scout4answers]

miragenews.com/compound-pro...

But now, UC Davis Health researchers have developed a new compound that could offer alternatives for patients with treatment-resistant tumors. The molecule is called LX-1. It simultaneously targets androgen receptor (AR) variants and the enzyme AKR1C3, which are both known to drive resistance.

“Prostate tumors can develop multiple resistance mechanisms that allow them to live without external androgen, negating efforts to treat them,” said Director of Urologic Research Allen Gao, who is also the Ralph de Vere White Professor. “Once resistance develops, patients have few therapeutic choices, and their survival rate is quite poor.”

Normally, androgen receptors need androgen to be activated. But these AR variants are active all the time, driving tumor growth even without androgen stimulation.

Prostate tumors have other tricks to evade treatment. In the face of androgen deprivation, they can even make their own androgen, creating a closed circuit that defies intervention. Tumors often hijack AKR1C3 to make androgens.

[Kaliber]

kewl …. I’ll take 2. Thanks for the post big guy.

❤️❤️❤️

[dockam in reply to Kaliber]

I want a 6 pack😂

[Kaliber in reply to dockam]

lol … some for now …some for later.😂😂😂

[dockam in reply to Kaliber]

Maybe just a 30 pack, just in case

[Kaliber in reply to dockam]

lol

[spw1]

I wish this or something like this was already in trial stage.

[GSDF]

👍🙂

[Daddyishealing]

Has anyone heard of this in trial in the us now or any trials that seem to be giving positive results that are less risky to the bone marrow?

[KocoPr]

Here is a list of AKR1C3 inhibitors from a chemical distributor. It’s not for purchase for human use, but some of these are already FDA approved drugs. You can also research these chemicals to gather further knowledge on this very important pathway

dcchemicals.com/search.do?a...